HomeNewsBusinessCOVID-19 is spurring demand for Robotic Process Automation platforms

COVID-19 is spurring demand for Robotic Process Automation platforms

According to a recent report, companies are likely to increase their RPA spend by 5 percent in the next 12 months. An IDC report said that the pandemic has put RPA in the spotlight as companies are realizing the role of RPA in business continuity as they move into the economic recovery phase.

September 24, 2020 / 15:24 IST
Story continues below Advertisement

As COVID-19 forced people to work from home and moved processes online, robotic process automation (RPA) has come out a winner. Firms offering RPA solutions have reported increased traction over the last few months, and this is likely to increase further in the country, say industry watchers.

RPA refers to the use of software to automate repeated manual tasks like payroll processing, onboarding of employees and processing orders.

Story continues below Advertisement

According to a study by Forrester Consulting, commissioned by RPA player UiPath, companies are likely to increase their RPA spend by 5 percent in the next 12 months. Market research firm IDC in a report said that the pandemic has put RPA in the spotlight as companies are realizing the role of RPA in business continuity as they move into the economic recovery phase.

This interest could mean that key RPA players such as UiPath and Automation Anywhere and other firms that offer RPA as their service stand to benefit from this wave.

COVID-19 Vaccine
Frequently Asked Questions

View more

How does a vaccine work?

A vaccine works by mimicking a natural infection. A vaccine not only induces immune response to protect people from any future COVID-19 infection, but also helps quickly build herd immunity to put an end to the pandemic. Herd immunity occurs when a sufficient percentage of a population becomes immune to a disease, making the spread of disease from person to person unlikely. The good news is that SARS-CoV-2 virus has been fairly stable, which increases the viability of a vaccine.

How many types of vaccines are there?

There are broadly four types of vaccine — one, a vaccine based on the whole virus (this could be either inactivated, or an attenuated [weakened] virus vaccine); two, a non-replicating viral vector vaccine that uses a benign virus as vector that carries the antigen of SARS-CoV; three, nucleic-acid vaccines that have genetic material like DNA and RNA of antigens like spike protein given to a person, helping human cells decode genetic material and produce the vaccine; and four, protein subunit vaccine wherein the recombinant proteins of SARS-COV-2 along with an adjuvant (booster) is given as a vaccine.

What does it take to develop a vaccine of this kind?

Vaccine development is a long, complex process. Unlike drugs that are given to people with a diseased, vaccines are given to healthy people and also vulnerable sections such as children, pregnant women and the elderly. So rigorous tests are compulsory. History says that the fastest time it took to develop a vaccine is five years, but it usually takes double or sometimes triple that time.
View more
+ Show